当前位置: 首页 » 政策法规 » 国外法规 »(EU) No 155/2014:拒绝批准某些食品健康声称,不涉及降低疾病风险和儿童成长、健康有关的声称(refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health)

(EU) No 155/2014:拒绝批准某些食品健康声称,不涉及降低疾病风险和儿童成长、健康有关的声称(refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health)

扫描二维码 分享好友和朋友圈
放大字体  缩小字体 2015-01-08 10:36:18  来源:EUROPE  浏览次数:3080
核心提示:2014年2月20日,欧盟发布委员会条例(EU) No 155/2014,拒绝批准12种食品健康声称。
发布单位
EUROPEAN COMMISSION
EUROPEAN COMMISSION
发布文号 (EU) No 155/2014
发布日期 2014-02-20 生效日期 暂无
有效性状态 废止日期 暂无
备注 2014年2月20日,欧盟发布委员会条例(EU) No 155/2014,拒绝批准12种食品健康声称,分别如下:1)L-酪氨酸对于天然形成多巴胺非常重要;2)食用铁可预防非更年期妇女过度脱发;3)瓜氨酸苹果酸盐:通过减少过量乳酸以维持三磷酸腺苷的含量,从而达到恢复肌肉疲劳的目的。4) Eff EXT™有助于维持关节柔韧性;5)磷虾油有助于改善敏感关节的舒适度;6)葡萄籽提取物有助于促进腿部静脉循环;7)葡萄籽提取物有助于减轻腿肿;8)每天食用500mgCynatine®有助于维持关节柔韧性;9)OXY 280有助于降低体重;10)葡萄籽提取物有助于消除水肿;11)Paullinia cupana Kunth(瓜拉纳)、茶树(L.)和Kuntze(绿茶)提取物组合产品有助于燃烧脂肪;12)番茄红素、维生素E、叶黄素和硒有助于皮肤美黑。

  COMMISSION REGULATION (EU) No 155/2014

  of 19 February 2014

  refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health

  (Text with EEA relevance)

  THE EUROPEAN COMMISSION,

  Having regard to the Treaty on the Functioning of the European Union,

  Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods (1), and in particular Article 18(5) thereof,

  Whereas:

  (1)

  Pursuant to Regulation (EC) No 1924/2006 health claims made on foods are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.

  (2)

  Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State. The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as ‘the Authority’ for a scientific assessment, as well as to the Commission and the Member States for information.

  (3)

  The Authority is to deliver an opinion on the health claim concerned.

  (4)

  The Commission is to decide on the authorisation of health claims taking into account the opinion delivered by the Authority.

  (5)

  Following an application from Vitabiotics Ltd, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of L-tyrosine and contribution to normal synthesis of dopamine (Question No EFSA-Q-2011-00319) (2). The claim proposed by the applicant was worded as follows: ‘L-tyrosine is essential for the natural formation of dopamine’.

  (6)

  On 20 July 2011, the Commission and the Member States received the scientific opinion from the Authority, which noted that the role of L-tyrosine in the normal synthesis of catecholamines for the general population has already been addressed with a favourable outcome in a previous opinion (3) in the context of evaluation of claims referred to in Article 13(1) of Regulation (EC) No 1924/2006 and that L-tyrosine is the starting point for the synthesis of all catecholamines, including dopamine. Thus, the Authority concluded that a cause and effect relationship had been established between the consumption of L-tyrosine in a protein adequate diet and contribution to normal synthesis of dopamine and proposed as appropriate conditions of use that ‘a food should be at least a source of protein as per Annex to Regulation (EC) No 1924/2006’.

  (7)

  The Commission and the Member States have considered whether the health claim reflecting those conclusions should be authorised under the proposed conditions of use, since authorisation may also legitimately be withheld if health claims do not comply with other general and specific requirements of Regulation (EC) No 1924/2006, even in the case of a favourable scientific assessment by the Authority. In the Authority’s response of 9 November 2012 to the request of the Commission, inter alia, for clarification in relation to the evidence submitted for the health claim on L-tyrosine and the proposed conditions of use, the Authority noted that its conclusions for this claim were based on the well established biochemical role of L-tyrosine, as contained in protein. It added that, on the basis of the evidence submitted, it could not provide a quantitative indication of the necessary daily intake of L-tyrosine per se to produce the beneficial physiological effect. Therefore, it is not possible to establish specific conditions for the use of this claim to ensure that L-tyrosine is contained in the final product in a quantity that will produce the beneficial physiological effect in accordance with point (i) of Article 5(1)(b) of Regulation (EC) No 1924/2006. In the absence of such specific conditions of use, the beneficial effect of the substance to which the claim relates cannot be assured and thus this claim could be misleading to the consumer. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (8)

  Following an application from Pierre Fabre Dermo-Cosmétique, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the consumption of iron and maintenance of normal hair growth (Question No EFSA-Q-2012-00059) (4). The claim proposed by the applicant was worded as follows: ‘Excessive hair loss in non-menopausal women’.

  (9)

  On 15 March 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the intake of iron and maintenance of normal hair growth. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (10)

  Following an application from Biocodex, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the consumption of citrulline-malate and faster recovery from muscle fatigue after exercise (Question No EFSA-Q-2011-00931) (5). The claim proposed by the applicant was worded as follows: ‘Maintenance of adenosine triphosphate (ATP) levels through reduction of lactates in excess for recovery from muscle fatigue’.

  (11)

  On 11 May 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of citrulline-malate and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (12)

  Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Eff EXT? and maintenance of normal joint mobility (Question No EFSA-Q-2012-00384) (6). The claim proposed by the applicant was worded, inter alia, as follows: ‘Contributes to support joint flexibility’.

  (13)

  On 14 December 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Eff EXT? and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (14)

  Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of krill oil and maintenance of joint comfort (Question No EFSA-Q-2012-00385) (7). The claim proposed by the applicant was worded, inter alia, as follows: ‘Helps to improve the comfort of sensitive joints’.

  (15)

  On 14 December 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of krill oil and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (16)

  Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Vitis vinifera L. seeds extract and normal venous blood flow (Question No EFSA-Q-2012-00387) (8). The claim proposed by the applicant was worded, inter alia, as follows: ‘Contributes to promote venous circulation in the legs’.

  (17)

  On 14 December 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Vitis vinifera L. seeds extract and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (18)

  Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Vitis vinifera L. seeds extract and ‘Helps to decrease swollen legs’ (Question No EFSA-Q-2012-00388) (9). The claim proposed by the applicant was worded, inter alia, as follows: ‘Helps to decrease swollen legs’.

  (19)

  On 14 December 2012, the Commission and the Member States received the scientific opinion from the Authority, which noted that the claim refers to the reduction of peripheral oedema in the context of chronic clinical conditions (e.g. chronic venous insufficiency) and concluded that on the basis of the data presented, such reduction of peripheral oedema in the context of chronic clinical conditions is a therapeutic target for their treatment.

  (20)

  Regulation (EC) No 1924/2006 complements the general principles of Directive 2000/13/EC of the European Parliament and of the Council of 20 March 2000 on the approximation of the laws of the Member States relating to the labelling, presentation and advertising of foodstuffs (10). Article 2(1)(b) of Directive 2000/13/EC provides that the labelling shall not attribute to any foodstuff the property of preventing, treating or curing a human disease, or refer to such properties. Accordingly, as the attribution of medicinal properties to foods is prohibited, the claim related to the effects of Vitis vinifera L. seeds extract and ‘Helps to decrease swollen legs’ should not be authorised.

  (21)

  Following an application from Roxlor Nutra LLC, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Cynatine? and maintenance of normal joint mobility (Question No EFSA-Q-2012-00570) (11). The claim proposed by the applicant was worded, inter alia, as follows: ‘Daily consumption of 500 mg of Cynatine? helps to support joint flexibility’.

  (22)

  On 14 December 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Cynatine? and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (23)

  Following an application from Actina, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of OXY 280 and reduction of body weight (Question No EFSA-Q-2012-00572) (12). The claim proposed by the applicant was worded, inter alia, as follows: ‘OXY 280 helps to lose weight’.

  (24)

  On 14 December 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of OXY 280 and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (25)

  Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Vitis vinifera L. seeds extract and ‘Helps to drain the body in case of water accumulation’ (Question No EFSA-Q-2012-00574) (13). The claim proposed by the applicant was worded, inter alia, as follows: ‘Helps to drain the body in case of water accumulation’.

  (26)

  On 14 December 2012, the Commission and the Member States received the scientific opinion from the Authority, which noted that the claimed effect refers to the maintenance of normal venous blood flow. The Authority noted also that the same health relationship was already subject to its assessment in a previous opinion (14) with an unfavourable outcome and that the reference provided for the scientific substantiation of this claim was already considered in the previous opinion. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (27)

  Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of Paullinia cupana Kunth (guarana) and Camellia sinensis (L.) Kuntze (green tea) extracts and reduction of body weight (Question No EFSA-Q-2012-00590) (15). The claim proposed by the applicant was worded, inter alia, as follows: ‘Helps to burn fat’.

  (28)

  On 14 December 2012, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of a combination of Paullinia cupana Kunth (guarana) and Camellia sinensis (L.) Kuntze (green tea) extracts and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (29)

  Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of a combination of lycopene, vitamin E, lutein and selenium and ‘Helps to prepare and activate tanning’ (Question No EFSA-Q-2012-00593) (16). The claim proposed by the applicant was worded, inter alia, as follows: ‘Helps to prepare and activate tanning’.

  (30)

  On 14 December 2012, the Commission and the Member States received the scientific opinion from the Authority, which noted that the claimed effect refers to increasing the pigmentation of the skin (i.e. tanning) which may contribute to the protection of the skin against UV-induced damage. The Authority noted also that the same health relationship was already subject to its assessment in a previous opinion (17) with an unfavourable outcome and that the reference provided for the scientific substantiation of this claim was the same as in the previous opinion. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (31)

  The health claim related to the effects of Vitis vinifera L. seeds extract and ‘Helps to decrease swollen legs’ is a health claim that attributes medicinal properties to the food that is the subject of the claim, which is prohibited for foods.

  (32)

  The health claims related to OXY 280 and to the combination of Paullinia cupana Kunth (guarana) and Camellia sinensis (L.) Kuntze (green tea) extracts are health claims as referred to in point (c) of Article 13(1) of Regulation (EC) No 1924/2006 and are therefore subject to the transitional period laid down in Article 28(6) of that Regulation. However, as the applications were not made before 19 January 2008, the requirement provided for in point (b) of Article 28(6) of that Regulation is not fulfilled, and therefore those claims may not benefit from the transitional period provided for in that Article.

  (33)

  The other health claims subject to this Regulation, are health claims as referred to in point (a) of Article 13(1) of Regulation (EC) No 1924/2006, which are subject to the transitional period laid down in Article 28(5) of that Regulation until the adoption of the list of permitted health claims provided that they comply with that Regulation.

  (34)

  The list of permitted health claims has been established by Commission Regulation (EU) No 432/2012 (18) and is applicable since 14 December 2012. As regards claims referred to in Article 13(5) of Regulation (EC) No 1924/2006 for which the evaluation by the Authority or consideration by the Commission has not been completed by 14 December 2012 and which by virtue of this Regulation are not included in the list of permitted health claims, it is appropriate to provide for a transitional period during which they may still be used, in order to allow both food business operators and the competent national authorities to adapt to the prohibition of such claims.

  (35)

  The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health and neither the European Parliament nor the Council have opposed them,

  HAS ADOPTED THIS REGULATION:

  Article 1

  1.   The health claims listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.

  2.   However, the health claims referred to in paragraph 1 used prior to the entry into force of this Regulation may continue to be used for a maximum period of six months after the entry into force of this Regulation.

  Article 2

  This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

  This Regulation shall be binding in its entirety and directly applicable in all Member States.

  Done at Brussels, 19 February 2014.

  For the Commission

  The President

  José Manuel BARROSO
 

ANNEX
Rejected health claims
Application — Relevant provisions of Regulation (EC) No 1924/2006
Nutrient, substance, food or food category
Claim
EFSA opinion reference
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
L-tyrosine
L-tyrosine is essential for the natural formation of dopamine
Q-2011-00319
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Iron
Excessive hair loss in non-menopausal women
Q-2012-00059
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Citrulline-malate
Maintenance of adenosine triphosphate (ATP) levels through reduction of lactates in excess for recovery from muscle fatigue
Q-2011-00931
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Eff EXT™
Contributes to support joint flexibility
Q-2012-00384
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Krill oil
Helps to improve the comfort of sensitive joints
Q-2012-00385
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Vitis vinifera L. seeds extract
Contributes to promote venous circulation in the legs
Q-2012-00387
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Vitis vinifera L. seeds extract
Helps to decrease swollen legs
Q-2012-00388
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Cynatine®
Daily consumption of 500 mg of Cynatine® helps to support joint flexibility
Q-2012-00570
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
OXY 280
OXY 280 helps to lose weight
Q-2012-00572
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Vitis vinifera L. seeds extract
Helps to drain the body in case of water accumulation
Q-2012-00574
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
A combination of Paullinia cupana Kunth (guarana) and Camellia sinensis (L.) Kuntze (green tea) extracts
Helps to burn fat
Q-2012-00590
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
A combination of lycopene, vitamin E, lutein and selenium
Helps to prepare and activate tanning
Q-2012-00593


 

食品伙伴网提供标准法规解读、舆情监控、合规咨询、申报注册等服务。
电询:0535-2129301
QQ:2891238009
食品标法圈
实时把握食品标法动态
请扫码关注食品标法圈

声明:

① 凡本网所有原始/编译文章及图片、图表的版权均属食品伙伴网所有,如要转载,需注明“信息来源:食品伙伴网”。
② 凡本网注明“信息来源:XXX(非食品伙伴网)”的作品,均转载自其他媒体,转载目的在于传递更多的信息,并不代表本网赞同其观点和对其真实性负责。
※ 邮箱:law#foodmate.net(发邮件时请将#换成@) QQ:139307733

 
 
[ 政策法规搜索 ]  [ 加入收藏 ]  [ 告诉好友 ]  [ 打印本文 ]  [ 关闭窗口 ]

 

 
 
按分类浏览
国家法规 (11358) 国外法规 (3603)
地方法规 (39742) 法规动态 (210)
法规解读 (2623) 其他法规 (506)
推荐国外法规
点击排行
按国家或地区浏览

法规中心  关于我们  广告业务  联系我们  信息服务

Processed in 0.311 second(s), 10 queries, Memory 4.56 M